Source: https://home.liebertpub.com/publications/industrial-biotechnology/140/for-authors
Timestamp: 2019-04-26 02:55:07+00:00

Document:
Industrial Biotechnology is the only journal dedicated to bioresearch for industrial and environmental applications, bridging early-stage R&D with commercialization for sustainable, cost-and eco-efficient production of chemicals, materials, consumer goods, and energy.
Industrial Biotechnology presents critical contributions to the scientific literature in chemistry, biology, biochemistry, and engineering, through stringently peer-reviewed Original Research (§2, 3), Short Communications (§10), Reviews (§11), Methods (§12), and Technical Notes (§13).
The Journal’s broad coverage spans the entirety of the industrial biotechnology field, presenting breaking developments in R&D and applied biotechnology for applications including bioenergy and biofuels, biomass, biorefineries, pulp and paper, textiles, food, beverage, and feed processing, detergents, synthetic biology, biodefense, nanobiotechnology; bioremediation, biomaterials (biofilms, biopolymers), and industrial enzymes.
Supplementing our peer-reviewed contributions is the Journal’s industry trade editorial content, including expert Feature Commentary (§14), industry, institute, and government Reports (§15), and News Updates on industrial biotech R&D and business developments (for News, e-mail press releases to vglaser@liebertpub.com).
2.1 Manuscripts submitted to the Journal must not be under consideration elsewhere (§8) and will be considered copyrighted to Mary Ann Liebert, Inc., publishers, and GEN Publishing, Inc., once accepted.
2.1.1. A Letter of Transmittal should accompany each peer-review submission (§3.3).
2.1.2. A completed Manuscript Submission and Copyright Agreement Form is required on acceptance (§8).
2.3 High-resolution artwork files must be uploaded as separate files from the manuscript. Illustrations should only be included within text documents to indicate placement. Artwork must be in EPS or TIFF format, and in CMYK (not RGB; see §4). Word, PowerPoint, and Excel files must be converted; non-digital images should be scanned (§4.8).
2.4 References must adhere to the citation style outlined in §6.
2.5 Manuscripts including reproduced data, text, etc., from previously copyrighted materials must be accompanied by permission of the other journal, book, or publisher/producer concerned.
3.1 All manuscripts for peer-review are to be submitted electronically online through Industrial Biotechnology’s web-based manuscripts service, Manuscript Central (http://mc.manuscriptcentral.com/indbiotech). New authors must Create an Account through link at uppermost top-right. Returning authors, log in only. Manuscript Central will then guide authors step-by-step through the online submission process.
3.2. Electronic manuscripts should be formatted double-spaced, with margins of 1" (one inch) on each side and ample space on top and bottom.
4.1. Electronic submission of art is required through Manuscript Central. Guidelines in sections 4.2 through 4.9 must be followed. Note in particular Industrial Biotechnology’s requirements for image file formats (§4.3, §4.8), color (§4.3), resolution (§4.4), and pre-submission verification (§4.9).
4.2. Do not include publishable illustrations as part of the manuscript text file. Artwork should not be included within the text document except to show placement and facilitate editors’ ensuring of accuracy.
Images should be in high-resolution TIFF or EPS formats, each sent in separate files clearly labeled (“AuthorSurname-Figure X.tif” or “AuthorSurname-Figure X.eps”). Do NOT submit JPEG files. Color art must be saved as CYMK not RGB; all RGB files will be converted to CYMK, which can introduce color variation.
Line illustrations must be minimum 1,200 dpi at a picture width of 4". Half-tone and color photos should be at a minimum of 300 dpi at a picture width of 4".
Do not repeat information stated in the text. Do not create tables for data that can be or is explained concisely in the text. Provide titles for each tables. Define all acronyms in table footnotes, designated using superscript letters unless continuous with the main manuscript’s footnotes. Neither names nor logos of manufacturers or commercial suppliers should be included in tables or figures, excepting names in tables dedicated to highlighting relevant suppliers for a particular editorial theme.
Use Arabic numerals to number tables. Figures should be numbered in the order cited in the text. A listing of all figure titles should be submitted with each manuscript, either as a page within the manuscript, or in a separate file named “AuthorSurname-FigureList.doc”.
A legend or caption should be supplied for each illustration, all compiled in one common file. All symbol definitions should appear in a separate figure legend, not as a key within the figure. Legends should be numbered consecutively (Arabic numerals) and included on a separate page within the manuscript or a separate Word file (named “AuthorSurname-Captions.doc”).
Adobe is the preferred software platform for images. Images prepared in PowerPoint, Excel, or Word should NOT be submitted (See §4.8.1 to convert these). Logos are not permitted in figures.
Manuscripts should generally be between 2,500 and 3,500 words, excluding references and abstract.
Concisely describe the technology platform/scientific discovery. Refrain from use of “Novel” or “New”. Significance or application may be briefly described in a subtitle.
250 words or fewer. No subheadings. References not permitted in abstracts.
Summarize background, significance, and novelty. No discussion of results should be included in the Introduction.
Sources of specific materials (including reagents, software, and instrumentation) should be stated and marked with ™ or ® if they are trademarked or registered, respectively. These marks should be included only at the product’s first mention within the body text. When citing specific brand names of products or technologies, please include in parentheses the manufacturer’s name and location (city, state/province, and, if outside the U.S., country). All acronyms and their definitions should be spelled out in a separate list on a page appearing immediately after the title page. Use only acronyms in text.
Results and Discussion in shorter papers may be combined into one section.
Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance. If no conflicts exist, the authors must state “No competing financial interests exist."
All references must be cited in the text using a superscript Arabic number, placed after any relevant punctuation within the phrase or sentence. Arrange the reference list in numeric order as cited in the text. Include only one article per reference number. Abbreviate journal names according to NIH National Library of Medicine's List of Journals Indexed for Medline.
* If four or less authors, list all four; if greater than four, list first three followed by et al.
Nakaoki T, Mei Y, Miller LM, et al. Candida antarctica lipase B catalyzed polymerization of lactones. Ind Biotechnol 2005;1(3):126-134.
Constable G and Somerville B. A Century of Innovation. Washington, DC: Joseph Henry Press, Washington, District of Columbia, 2001:25-36.
Delagrave S et al. Combinatorial mutagenesis algorithms, digital imaging spectroscopy, and solid -phase assays for directed evolution. In: Svendsen A, ed. Enzyme Functionality. New York, NY: Marcel Dekker, 2004:507-523.(2004).
Hess R. Feedstock assembly for a billion tons of biomass. In: First International Biorefinery Workshop (presentation). Washington, DC (July, 20-21, 2005).
For included material published elsewhere, written permission is required from the publisher/producer concerned. This must be provided at time of manuscript submission.
Any other publications from which figures or tables are taken must be listed in the reference list. An appropriate credit line should be included in the relevant figure legend or table footnote.
Page proofs are sent to corresponding authors via e-mail. Please ensure that any e-mail filters installed will accept messages from indbiotech.com and liebertpub.com domains.
Once a paper has been accepted and edited, the corresponding author will receive page proofs. Because Industrial Biotechnology is a rapid-publication journal, editors request that page proofs containing corrections be returned to the Publisher within 484 hours of receipt. If the corresponding author expects to be unavailable at the time proofs are anticipated, please notify the Executive Editor and provide an alternate corresponding author and full contact information for that person (phone, fax, e-mail and physical mailing address).
Short Communications are concise presentations of peer-reviewed original research: adaptations or new applications of current tools, technologies, and methods, or new procedures or products of broader interest to the industrial biotechnology communities. The standard for originality of contribution to the research is relaxed compared to that for Original Research; however, scientific and/or commercial significance, and relevance to industrial biotechnology, must be clear. Short Communications should be between 1,000 and 2,000 words (not including a short abstract of 75 words or fewer) and contain a maximum of 6 graphics (including tables) and up to 20 references. Other than these stipulations, information in §2–9 pertains.
A Review is a comprehensive, authoritative, scholarly survey of technologies, platforms, protocols, and literature. Industrial Biotechnology Reviews should be balanced, to focus beyond the research, product, or platform of a single company or laboratory, to contextualize all current, major technologies/discoveries in the particular area being reviewed (e.g., reviewers should indicate competitor products/platforms in discussions and/or tables or lists). Reviews should be broadly applicable to varied industrial biotechnology subsectors. Limit references to 100. All Reviews are subject to full peer-review. Other than these stipulations, all relevant information in §2–9 pertains.
Methods papers describe application of a particular technology or protocol, with supporting data clearly presented. Methods are now subject to peer-review. They are intended for rapid dissemination of current technologies, with intent to foster collaboration, client partnerships, and scientific dialogue. Methods papers should be data-rich; these are not marketing pieces. The strength of a particular technology or application should be apparent from the data itself. Methods pieces are generally between 1,000 and 2,000 words. Abstracts not required. Acronyms should be used and explained as appropriate. A maximum of 6 graphics is requested, including tables, and up to 25 references. Other than these stipulations, information in §2–9 pertains.
Letters to the Editor(s) are welcomed, but with a 500 word limit and no more than one (1) table OR figure, and with a maximum of four (4) references.
Feature Commentary articles are expert-authored pieces (1,000- to 3,000-words) about policy, funding, markets, business, legal issues, or science trends, of general relevance to the broad international readership in industrial biotechnology across various sectors. Figures are welcome though not required. A maximum of 30 references is requested. Commentaries are not subject to peer-review but may be informally reviewed by editorial board members with appropriate expertise.
All Feature Commentaries are edited as per Industrial Biotechnology’s style guide. Authors receive page proofs for review before publication.
Industrial Biotechnology publishes, in excerpt or whole, important industry, government, or institute reports from international sources on science and market trends and opportunities. All reports must be in the public domain, unless copyright permission is granted to GEN Publishing, Inc., and Mary Ann Liebert, Inc., publishers, for use in Industrial Biotechnology and related publications. All authors and sources are cited, with contact information, for potential purchasers of the full reports.
Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.
Industrial Biotechnology is owned and published by GEN Publishing, Inc., a Mary Ann Liebert, Inc., company. Editorial headquarters: 140 Huguenot Street, New Rochelle, New York 10801. Phone: (914) 740-2100. Fax: (914) 740-2101.
Our dynamic Author Benefits Program provides you with end-to-end benefits that ensure your hard work pays off and your published manuscript gets the attention it deserves not just upon publication, but permanently.
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
At this time we allow authors to choose between the CC-BY or CC-BY-NonCommercial license. A limited number of journals offer NonCommercial licenses exclusively.
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email openaccess@liebertpub.com.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email openaccess@liebertpub.com or visit Liebert Open Access for more information.

References: §4
 §6
 §4
 §4
 §2
 §2
 §2